Pregnancy changes the maternal immune system in ways that make some infections more dangerous than they would be outside pregnancy. Influenza in a pregnant woman is more likely to lead to severe illness, hospitalisation and pneumonia than influenza in a non-pregnant adult of the same age. COVID-19 in pregnancy carries a higher risk of severe disease and adverse pregnancy outcomes than COVID-19 in non-pregnant women. Tetanus from a contaminated delivery or wound during pregnancy or the puerperium is almost universally fatal without vaccination protection. The maternal benefit of vaccination is therefore not a small bonus — it is a serious protection in its own right.

The second benefit is the one that is unique to pregnancy vaccination: maternal antibodies cross the placenta, particularly in the third trimester, and enter the baby's circulation. The newborn is born with a passive layer of immunity against the conditions the mother has been vaccinated for, and that protection lasts for weeks to months — exactly the window in which the baby is too young to receive most of its own vaccines and is most vulnerable to severe infection. This is why a Tdap dose between 27 and 36 weeks is so highly recommended: it protects the newborn against pertussis (whooping cough), a condition that is especially severe in young infants, during precisely the months when the baby cannot yet be vaccinated against it.

The same logic applies to influenza: a flu shot during pregnancy protects the mother from severe flu and also protects the baby through transferred antibodies for the first six months of life, before the baby is eligible for its own flu vaccine. For the broader picture of how each trimester evolves and what to expect at each antenatal visit, see What to Expect Week by Week During Pregnancy.

Three vaccines form the core of the pregnancy schedule recommended for almost every Indian woman regardless of risk profile: tetanus protection (either the older two-dose TT schedule or the newer single Tdap), influenza, and COVID-19. All three are inactivated vaccines, all three have a strong safety record in pregnancy across millions of administered doses globally, and all three are either fully free at government facilities or available at affordable cost in the private sector.

Tetanus toxoid (TT) has been part of India's universal antenatal care for decades and is one of the great public-health success stories of the country, having driven neonatal tetanus deaths down by more than 95 percent. The newer Tdap (tetanus, diphtheria and acellular pertussis) is now preferred under updated FOGSI guidelines because it adds pertussis protection for the newborn at a critical time. Influenza vaccination is layered on top, especially during the Indian flu season from October to February, and is now embedded into PMSMA visits at government facilities. COVID-19 vaccination follows the latest national schedule and is approved across all trimesters.

Beyond these core three, there is a second tier of vaccines that are offered based on individual risk — Hepatitis B if not previously vaccinated, pneumococcal for chronic conditions such as asthma or diabetes, and meningococcal for travel or outbreak situations. These are not routine for every pregnant woman but are important for those who fit the indication. For a fuller understanding of how antenatal scans and labs interact with the vaccination schedule, see Understanding Scans, Labs & Reports: A Complete India Pregnancy Guide.

The older RCH programme schedule, still followed across many government facilities, recommends two doses of tetanus toxoid four weeks apart, typically given at 16 to 20 weeks and again at 20 to 24 weeks for a first pregnancy. For subsequent pregnancies within five years of completed TT immunisation, a single booster dose suffices. This schedule is free at all government facilities and is the schedule a woman will encounter at a PMSMA clinic or a primary health centre.

Updated FOGSI guidelines, in line with global ACOG and CDC recommendations, now prefer a single dose of Tdap (tetanus, diphtheria, acellular pertussis) given between 27 and 36 weeks of pregnancy in every pregnancy, regardless of previous tetanus immunisation status. The reason Tdap is preferred over plain TT is that it adds protection against pertussis (whooping cough), which is severe and sometimes fatal in young infants, by transferring maternal pertussis antibodies to the baby in the third trimester when the antibody transfer is most efficient. Tdap is available in the private sector at most maternity centres for around 1500 to 3000 rupees per dose, and is increasingly available at empanelled public hospitals.

Both vaccines are extremely safe in pregnancy. Mild soreness at the injection site and occasional low-grade fever are the most common effects; serious adverse reactions are very rare. The protection achieved is profound — neonatal tetanus, once a leading cause of newborn death in India, is now extremely rare in vaccinated mothers' babies. Coverage under PMSMA and JSSK ensures that no Indian woman should miss out on this protection because of cost.

The influenza vaccine recommended in pregnancy is the inactivated injectable form, never the live nasal-spray version. It is recommended in any trimester by the WHO, the US CDC, ACOG and the Indian FOGSI, with the strongest emphasis on the October-to-February window in India when influenza activity peaks. A single annual dose provides protection for about six months. Pregnant women are at higher risk of severe flu, hospitalisation and pneumonia than non-pregnant adults, and the maternal vaccine also protects the baby for the first six months of life through transferred antibodies — before the baby is eligible for its own flu shot.

Cost in the private sector ranges from about 500 rupees for the basic trivalent or quadrivalent shot to 1500 rupees at premium private hospitals. The vaccine is offered free under PMSMA at government facilities during the flu season, though stocks vary by state and centre. For pregnant women with chronic respiratory conditions such as asthma, the flu shot is even more strongly recommended, and an evening of mild soreness or a low-grade fever is well worth the protection.

The vaccine is well tolerated. The most common reactions are tenderness at the injection site, mild fatigue and an occasional low-grade fever for a day. Serious allergic reactions are very rare, and women with severe egg allergy can usually still receive the shot in a supervised setting because modern flu vaccines contain only trace amounts of egg protein.

Both the Indian Ministry of Health and Family Welfare and the World Health Organization recommend COVID-19 vaccination in pregnancy. The two main vaccines used in India in pregnancy are Covaxin (an inactivated whole-virus vaccine developed by Bharat Biotech) and Covishield (an adenovirus vector vaccine developed by Oxford-AstraZeneca and manufactured by the Serum Institute of India). Both have been used across all trimesters and during breastfeeding, with extensive safety data from millions of doses given to pregnant women globally.

Where mRNA vaccines such as Pfizer-BioNTech are available — they are not widely available in India outside selected private and institutional channels — they are preferred internationally for pregnant women based on the largest body of pregnancy-specific safety evidence. Booster doses are recommended in line with the latest national schedule, which has evolved as the pandemic phase has changed; pregnant women should follow the schedule current at the time of their pregnancy and discuss timing with their OB-GYN.

Side effects in pregnant women are similar to those in non-pregnant adults — soreness at the injection site, fatigue, occasional fever for a day, mild headache. Serious adverse effects are very rare. The maternal vaccine also provides the baby with some passive immunity through transferred antibodies in the third trimester. The myth that COVID vaccines cause infertility or harm pregnancy outcomes has been comprehensively debunked across many large studies.

The Indian government delivers maternal vaccination through a layered set of programmes that, taken together, mean no Indian woman should be without access to the core vaccines because of cost. The Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA), launched in 2016, provides a free comprehensive antenatal check-up — including blood pressure, weight, urine, blood tests and vaccination — on the ninth of every month at government health facilities across the country. Almost every PMSMA visit includes the relevant tetanus dose, influenza shot during season, and COVID-19 vaccination as per the current schedule.

The Janani Suraksha Yojana (JSY) is a cash-incentive programme that encourages institutional delivery and ensures that the maternal vaccination schedule is completed before birth. The Janani Shishu Suraksha Karyakaram (JSSK) provides free delivery, free drugs, free diagnostics, free blood transfusion and free transport for pregnant women and sick newborns at government hospitals, removing the cost barrier completely for the most vulnerable. All three programmes sit under the broader Mission Indradhanush umbrella, the national universal immunisation programme that aims for full vaccination of every pregnant woman and child in India.

On the ground, the ASHA (Accredited Social Health Activist) worker is often the bridge between these programmes and the family. ASHA workers track every pregnancy in their community, remind families about the next antenatal visit and vaccination, and accompany women to PMSMA clinics where needed. For families navigating support systems during pregnancy, including how the wider household can help, see Building Your Village: Partner, Mother‑in‑Law & Community Health Worker.

Beyond the universally recommended tetanus, flu and COVID vaccines, a second tier of vaccines is offered selectively based on individual risk profile and circumstances. Hepatitis B vaccination is recommended in pregnancy for any woman who has not previously been vaccinated, and the standard three-dose schedule (0, 1 and 6 months) can be started safely at any point in pregnancy. Hepatitis B is particularly important to prevent because mother-to-baby transmission of Hepatitis B at birth can lead to chronic infection in the baby.

Pneumococcal vaccination is recommended for pregnant women with chronic respiratory disease such as asthma, with diabetes, with chronic kidney or heart disease, or who are immunocompromised. The polysaccharide pneumococcal vaccine (PPSV23) is inactivated and can be given safely during pregnancy when indicated. Meningococcal vaccination is recommended for pregnant women planning to travel for Hajj or to areas with active meningococcal outbreaks, and for those in specific high-risk medical categories.

Healthcare workers, women travelling internationally, women living in outbreak areas, and women with chronic medical conditions all may need additional vaccines that fall outside the standard schedule. The right approach in any such situation is a pre-pregnancy or first-trimester consultation with the OB-GYN to map out which vaccines are needed, which can be given during pregnancy and which need to be deferred to the postpartum period.

Live attenuated vaccines — vaccines that contain a weakened form of the actual virus — are not given during pregnancy. The theoretical concern is that the weakened virus, although safe in non-pregnant individuals, could in principle cross the placenta and affect the developing fetus. Although the actual evidence of harm is limited (and inadvertent vaccination has not been linked to clear fetal harm in observational data), the precautionary principle is firmly applied and these vaccines are deferred to before conception or to the postpartum period.

The live vaccines to avoid in pregnancy include MMR (measles, mumps, rubella), varicella (chicken pox), oral polio vaccine (OPV), BCG (the tuberculosis vaccine usually given in infancy in India), yellow fever vaccine (unless travel to a yellow fever country is unavoidable and the risk-benefit calculation favours vaccination), and HPV (human papillomavirus, generally deferred to postpartum even though the inactivated nature of newer HPV vaccines makes the theoretical risk lower).

If a live vaccine is inadvertently given before pregnancy is recognised, the standard advice is reassurance — observational data on inadvertent rubella vaccination in early pregnancy, for example, has not shown harm — but the situation should be discussed with the OB-GYN and documented. All of these live vaccines can be given safely after delivery, including during breastfeeding (the live virus from the vaccine does not transmit through breast milk), so the postpartum visit is an important opportunity to catch up.

The postpartum period is the standard opportunity to receive any live vaccines that had to be deferred during pregnancy, and to complete any inactivated vaccine series that were started but not finished. The four main catch-up vaccines are MMR (for women who are not already immune to measles, mumps and rubella based on prior vaccination or natural infection), varicella (for women without prior chicken pox exposure or vaccination), HPV (now licensed up to age 45 in many countries, although the strongest benefit is for women under 26), and the remaining doses of any Hepatitis B series started in pregnancy.

All of these vaccines are safe during breastfeeding. The live virus from the MMR and varicella vaccines does not transmit through breast milk in any clinically meaningful way, and there is no need to interrupt breastfeeding for vaccination. The standard approach is to administer the catch-up at the 6-week postpartum visit alongside the routine review, and to discuss the next dose timing if a multi-dose series is involved.

For families who are also considering future pregnancies, the postpartum catch-up is particularly important — being fully vaccinated against rubella before the next pregnancy, for instance, removes a small but real risk of congenital rubella syndrome in a future baby. Vaccination also pairs with a strong nutritional foundation that supports the recovering immune system and breastfeeding; for the food side of postpartum and pregnancy recovery, see Indian Superfoods During Pregnancy: Nutrition, Benefits & Recipes. For more on the HPV vaccine specifically and the Indian options including the indigenous Cervavac, see The HPV Vaccine in India: Cervavac, Gardasil, and What Every Family Should Know.

Vaccine hesitancy is a real phenomenon in India, fed by misinformation on social media, by genuine worry about anything new being given during pregnancy, and sometimes by family pressure from older relatives whose own pregnancies happened in an era of fewer vaccines. The right response to hesitancy is not pressure or dismissal — it is conversation, with evidence, with respect, and with time. The first step is to listen to the specific concern. Worry about COVID-19 vaccines and infertility, worry about Tdap causing autism in the baby, worry about flu vaccine being unnecessary because the woman feels fine, worry about needing several injections in pregnancy — each has a specific and respectful answer based on the data.

Tdap and influenza vaccines have been studied in millions of pregnancies globally without evidence of fetal harm; the COVID-19 vaccines have been studied in hundreds of thousands of pregnancies with reassuring safety data; the link between MMR and autism was based on a single small fraudulent paper that has been retracted and disproven by dozens of large subsequent studies. The mother who chooses not to vaccinate is not protecting her baby — she is leaving her baby unprotected in the first months when the baby's own immune system cannot yet make these antibodies.

PMSMA visits, ASHA worker home visits, and the OB-GYN consultation are all good moments for the calm, evidence-based conversation that addresses the specific concern. Many Indian women are also reassured by hearing that their friends, sisters and colleagues went through pregnancy vaccinations without incident and now have healthy children. Cultural framing matters too — the question is not what our mothers and grandmothers did, but what gives our babies the best possible start. Indian babies born to vaccinated mothers have measurably better health outcomes than those born to unvaccinated mothers, and that is the framing that often shifts the conversation.